| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 29 | 2024 | 543 | 7.790 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 21 | 2024 | 236 | 6.880 |
Why?
|
| Biomarkers, Tumor | 12 | 2024 | 203 | 4.040 |
Why?
|
| Autoantibodies | 5 | 2021 | 64 | 1.880 |
Why?
|
| Multiple Pulmonary Nodules | 3 | 2022 | 11 | 1.750 |
Why?
|
| Insulin-Like Growth Factor I | 6 | 2024 | 59 | 1.360 |
Why?
|
| Biomarkers | 9 | 2024 | 544 | 1.250 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2017 | 206 | 1.090 |
Why?
|
| Immunoassay | 3 | 2018 | 37 | 1.060 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 3 | 2015 | 10 | 0.930 |
Why?
|
| Body Composition | 2 | 2024 | 68 | 0.910 |
Why?
|
| Humans | 48 | 2024 | 25973 | 0.880 |
Why?
|
| Prognosis | 10 | 2024 | 784 | 0.870 |
Why?
|
| Solitary Pulmonary Nodule | 2 | 2015 | 14 | 0.870 |
Why?
|
| Adenocarcinoma | 5 | 2018 | 135 | 0.860 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2020 | 68 | 0.850 |
Why?
|
| Middle Aged | 21 | 2024 | 8775 | 0.790 |
Why?
|
| Neoplasm Staging | 7 | 2024 | 360 | 0.780 |
Why?
|
| Aged | 21 | 2024 | 8732 | 0.740 |
Why?
|
| Immunotherapy | 2 | 2024 | 53 | 0.730 |
Why?
|
| Early Detection of Cancer | 5 | 2022 | 102 | 0.720 |
Why?
|
| Cachexia | 2 | 2019 | 11 | 0.690 |
Why?
|
| Aged, 80 and over | 13 | 2024 | 4642 | 0.690 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 15 | 0.690 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2019 | 32 | 0.690 |
Why?
|
| Female | 25 | 2024 | 14735 | 0.660 |
Why?
|
| Male | 24 | 2024 | 14280 | 0.660 |
Why?
|
| HLA Antigens | 2 | 2021 | 13 | 0.620 |
Why?
|
| Algorithms | 7 | 2022 | 345 | 0.620 |
Why?
|
| Erlotinib Hydrochloride | 2 | 2020 | 11 | 0.620 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2018 | 6 | 0.580 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2018 | 15 | 0.570 |
Why?
|
| Syndecan-1 | 1 | 2018 | 5 | 0.570 |
Why?
|
| Vimentin | 2 | 2016 | 2 | 0.570 |
Why?
|
| Neovascularization, Pathologic | 2 | 2015 | 36 | 0.570 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 66 | 0.560 |
Why?
|
| Nerve Growth Factors | 1 | 2018 | 37 | 0.550 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2017 | 33 | 0.520 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2013 | 19 | 0.510 |
Why?
|
| Lymphatic Metastasis | 3 | 2012 | 88 | 0.500 |
Why?
|
| Kidney Transplantation | 2 | 2016 | 115 | 0.500 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2017 | 242 | 0.500 |
Why?
|
| Cytokines | 2 | 2014 | 225 | 0.470 |
Why?
|
| Graft Rejection | 2 | 2016 | 66 | 0.460 |
Why?
|
| Adult | 12 | 2018 | 7666 | 0.450 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2014 | 10 | 0.450 |
Why?
|
| Predictive Value of Tests | 5 | 2014 | 466 | 0.450 |
Why?
|
| Cohort Studies | 7 | 2024 | 1806 | 0.430 |
Why?
|
| Doxazosin | 1 | 2013 | 1 | 0.420 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2013 | 1 | 0.420 |
Why?
|
| Immunoglobulin G | 3 | 2022 | 71 | 0.420 |
Why?
|
| Melanins | 1 | 2013 | 6 | 0.420 |
Why?
|
| Chloroquine | 1 | 2013 | 7 | 0.420 |
Why?
|
| Sulfonamides | 1 | 2013 | 44 | 0.410 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2013 | 11 | 0.400 |
Why?
|
| Multivariate Analysis | 4 | 2017 | 326 | 0.390 |
Why?
|
| Immunoglobulin M | 2 | 2022 | 12 | 0.390 |
Why?
|
| C-Peptide | 1 | 2011 | 5 | 0.370 |
Why?
|
| Retrospective Studies | 7 | 2019 | 3358 | 0.370 |
Why?
|
| Sensitivity and Specificity | 3 | 2022 | 473 | 0.370 |
Why?
|
| Cell Line, Tumor | 7 | 2020 | 253 | 0.360 |
Why?
|
| Blood Chemical Analysis | 1 | 2010 | 17 | 0.340 |
Why?
|
| Survival Analysis | 3 | 2021 | 258 | 0.340 |
Why?
|
| Hematologic Tests | 1 | 2010 | 6 | 0.340 |
Why?
|
| Protein Array Analysis | 1 | 2010 | 11 | 0.340 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2020 | 55 | 0.330 |
Why?
|
| ErbB Receptors | 4 | 2020 | 54 | 0.320 |
Why?
|
| Area Under Curve | 4 | 2014 | 63 | 0.310 |
Why?
|
| Lymph Nodes | 1 | 2009 | 72 | 0.300 |
Why?
|
| Disease-Free Survival | 3 | 2017 | 174 | 0.290 |
Why?
|
| Treatment Outcome | 6 | 2024 | 3400 | 0.290 |
Why?
|
| Risk Assessment | 4 | 2017 | 603 | 0.280 |
Why?
|
| Body Weight | 3 | 2024 | 132 | 0.270 |
Why?
|
| Antigens, Neoplasm | 2 | 2021 | 41 | 0.260 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 337 | 0.240 |
Why?
|
| Gene Expression Profiling | 2 | 2024 | 133 | 0.240 |
Why?
|
| Animals | 11 | 2020 | 3503 | 0.240 |
Why?
|
| Antibodies, Viral | 2 | 2022 | 50 | 0.230 |
Why?
|
| Proteomics | 2 | 2018 | 84 | 0.220 |
Why?
|
| Young Adult | 4 | 2018 | 1942 | 0.210 |
Why?
|
| Chondrocytes | 3 | 2014 | 154 | 0.210 |
Why?
|
| ROC Curve | 2 | 2014 | 141 | 0.210 |
Why?
|
| Reproducibility of Results | 3 | 2014 | 649 | 0.210 |
Why?
|
| Prospective Studies | 3 | 2024 | 1702 | 0.210 |
Why?
|
| Pneumonectomy | 2 | 2017 | 76 | 0.200 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2016 | 160 | 0.200 |
Why?
|
| Survival Rate | 2 | 2018 | 333 | 0.200 |
Why?
|
| Mutation | 3 | 2020 | 341 | 0.200 |
Why?
|
| Vaccines | 1 | 2022 | 7 | 0.200 |
Why?
|
| Immunoglobulin E | 1 | 2022 | 9 | 0.200 |
Why?
|
| Immunoglobulin A | 1 | 2022 | 13 | 0.200 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2024 | 117 | 0.200 |
Why?
|
| Complement C1q | 1 | 2022 | 7 | 0.190 |
Why?
|
| Sarcopenia | 2 | 2019 | 29 | 0.190 |
Why?
|
| Seroconversion | 1 | 2022 | 1 | 0.190 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2022 | 5 | 0.190 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2022 | 16 | 0.190 |
Why?
|
| Body Mass Index | 1 | 2024 | 449 | 0.190 |
Why?
|
| Organoids | 1 | 2021 | 7 | 0.180 |
Why?
|
| Neoplasms | 2 | 2021 | 230 | 0.180 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2015 | 648 | 0.180 |
Why?
|
| Precision Medicine | 1 | 2021 | 24 | 0.180 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 1758 | 0.180 |
Why?
|
| Pilot Projects | 1 | 2022 | 390 | 0.180 |
Why?
|
| Neoplasm Invasiveness | 3 | 2017 | 91 | 0.180 |
Why?
|
| Bone Morphogenetic Protein 7 | 2 | 2011 | 30 | 0.180 |
Why?
|
| B7-H1 Antigen | 1 | 2021 | 7 | 0.180 |
Why?
|
| Proportional Hazards Models | 3 | 2017 | 332 | 0.170 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 18 | 0.170 |
Why?
|
| Observer Variation | 1 | 2021 | 97 | 0.170 |
Why?
|
| Disease Progression | 2 | 2014 | 655 | 0.170 |
Why?
|
| Endothelin-1 | 1 | 2020 | 3 | 0.170 |
Why?
|
| Biochemistry | 1 | 2000 | 1 | 0.170 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 110 | 0.170 |
Why?
|
| Cardiovascular Diseases | 1 | 2024 | 307 | 0.170 |
Why?
|
| Mass Screening | 1 | 2022 | 170 | 0.170 |
Why?
|
| Proteins | 1 | 2000 | 60 | 0.160 |
Why?
|
| Weight Loss | 2 | 2019 | 122 | 0.160 |
Why?
|
| Receptors, CXCR | 1 | 2019 | 1 | 0.160 |
Why?
|
| Patient Selection | 1 | 2021 | 190 | 0.160 |
Why?
|
| Esophagectomy | 1 | 2019 | 23 | 0.160 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2019 | 6 | 0.160 |
Why?
|
| Protein Binding | 3 | 2014 | 121 | 0.160 |
Why?
|
| Esophageal Neoplasms | 1 | 2019 | 50 | 0.150 |
Why?
|
| RNA, Small Untranslated | 1 | 2018 | 1 | 0.150 |
Why?
|
| Channelopathies | 1 | 2018 | 6 | 0.150 |
Why?
|
| CA1 Region, Hippocampal | 1 | 2018 | 9 | 0.150 |
Why?
|
| Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels | 1 | 2018 | 11 | 0.150 |
Why?
|
| Cell Movement | 2 | 2016 | 79 | 0.140 |
Why?
|
| Carcinoma, Large Cell | 1 | 2018 | 12 | 0.140 |
Why?
|
| Transcriptome | 3 | 2024 | 82 | 0.140 |
Why?
|
| Pyramidal Cells | 1 | 2018 | 35 | 0.140 |
Why?
|
| Neuronal Plasticity | 1 | 2018 | 48 | 0.140 |
Why?
|
| SOS1 Protein | 1 | 2016 | 4 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2016 | 12 | 0.130 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2016 | 14 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 165 | 0.130 |
Why?
|
| Kidney Tubules | 1 | 2016 | 6 | 0.130 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2016 | 42 | 0.130 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 63 | 0.130 |
Why?
|
| Cattle | 2 | 2013 | 122 | 0.130 |
Why?
|
| Muscle, Skeletal | 1 | 2019 | 374 | 0.130 |
Why?
|
| Cognition | 1 | 2024 | 1250 | 0.120 |
Why?
|
| Metformin | 1 | 2016 | 16 | 0.120 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 36 | 0.120 |
Why?
|
| Computational Biology | 2 | 2014 | 20 | 0.120 |
Why?
|
| Aggrecans | 2 | 2013 | 54 | 0.120 |
Why?
|
| Risk Factors | 3 | 2024 | 2237 | 0.120 |
Why?
|
| Mice, Transgenic | 4 | 2019 | 214 | 0.120 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2015 | 2 | 0.120 |
Why?
|
| Repressor Proteins | 1 | 2015 | 38 | 0.120 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2011 | 58 | 0.110 |
Why?
|
| Collagen Type X | 1 | 2014 | 3 | 0.110 |
Why?
|
| Kidney Failure, Chronic | 1 | 2016 | 125 | 0.110 |
Why?
|
| Mice | 5 | 2020 | 1352 | 0.110 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2015 | 51 | 0.110 |
Why?
|
| Minnesota | 1 | 2014 | 6 | 0.110 |
Why?
|
| Hematologic Neoplasms | 1 | 2014 | 19 | 0.110 |
Why?
|
| Microspheres | 1 | 2014 | 24 | 0.110 |
Why?
|
| Cell Differentiation | 1 | 2014 | 132 | 0.110 |
Why?
|
| Metabolic Syndrome | 1 | 2014 | 56 | 0.110 |
Why?
|
| Choroid | 1 | 2013 | 1 | 0.110 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2013 | 1 | 0.110 |
Why?
|
| Iris | 1 | 2013 | 2 | 0.110 |
Why?
|
| Biological Assay | 1 | 2013 | 7 | 0.110 |
Why?
|
| Illinois | 1 | 2014 | 235 | 0.110 |
Why?
|
| Reference Values | 1 | 2014 | 181 | 0.110 |
Why?
|
| src-Family Kinases | 1 | 2013 | 7 | 0.100 |
Why?
|
| Collagen Type IV | 2 | 2004 | 4 | 0.100 |
Why?
|
| Feasibility Studies | 1 | 2014 | 210 | 0.100 |
Why?
|
| Gene Expression Regulation | 2 | 2014 | 266 | 0.100 |
Why?
|
| In Vitro Techniques | 1 | 2013 | 166 | 0.100 |
Why?
|
| Postoperative Complications | 1 | 2019 | 901 | 0.100 |
Why?
|
| Chondroitin Sulfates | 1 | 2013 | 6 | 0.100 |
Why?
|
| Cell Proliferation | 3 | 2021 | 173 | 0.100 |
Why?
|
| Chemokine CCL3 | 1 | 2013 | 8 | 0.100 |
Why?
|
| Granuloma | 1 | 2013 | 13 | 0.100 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2013 | 14 | 0.100 |
Why?
|
| Chemokine CXCL12 | 1 | 2013 | 9 | 0.100 |
Why?
|
| Amino Acid Sequence | 5 | 2015 | 153 | 0.100 |
Why?
|
| Interleukin-10 | 1 | 2013 | 18 | 0.100 |
Why?
|
| Respiratory Tract Infections | 1 | 2013 | 24 | 0.100 |
Why?
|
| Interleukin-1beta | 1 | 2013 | 48 | 0.100 |
Why?
|
| Molecular Sequence Data | 5 | 2015 | 190 | 0.100 |
Why?
|
| Interleukin-6 | 1 | 2013 | 74 | 0.100 |
Why?
|
| Chronic Disease | 1 | 2014 | 404 | 0.100 |
Why?
|
| Decision Support Techniques | 1 | 2012 | 45 | 0.100 |
Why?
|
| Pneumonia | 1 | 2013 | 70 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2024 | 76 | 0.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2013 | 181 | 0.090 |
Why?
|
| Obesity | 1 | 2014 | 297 | 0.090 |
Why?
|
| Animal Experimentation | 1 | 2010 | 3 | 0.090 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2010 | 8 | 0.090 |
Why?
|
| Radiography | 1 | 2013 | 616 | 0.090 |
Why?
|
| Serum | 1 | 2010 | 7 | 0.090 |
Why?
|
| Antibodies, Neoplasm | 1 | 2010 | 12 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2017 | 174 | 0.080 |
Why?
|
| Intervertebral Disc | 1 | 2010 | 117 | 0.080 |
Why?
|
| Mass Spectrometry | 3 | 2014 | 33 | 0.080 |
Why?
|
| Case-Control Studies | 1 | 2010 | 572 | 0.070 |
Why?
|
| Sodium Dodecyl Sulfate | 1 | 2008 | 2 | 0.070 |
Why?
|
| Alzheimer Disease | 2 | 2018 | 2036 | 0.070 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2008 | 26 | 0.070 |
Why?
|
| Phosphoproteins | 1 | 2008 | 25 | 0.070 |
Why?
|
| Preoperative Care | 1 | 2009 | 120 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2020 | 22 | 0.070 |
Why?
|
| Metals | 1 | 2008 | 136 | 0.070 |
Why?
|
| Cartilage, Articular | 1 | 2011 | 417 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2015 | 142 | 0.060 |
Why?
|
| Signal Transduction | 3 | 2014 | 437 | 0.060 |
Why?
|
| Melanoma | 2 | 2004 | 49 | 0.060 |
Why?
|
| Hyaluronan Receptors | 1 | 2004 | 5 | 0.060 |
Why?
|
| Metalloproteases | 1 | 2004 | 6 | 0.060 |
Why?
|
| Peptide Fragments | 2 | 2004 | 75 | 0.050 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2024 | 45 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 38 | 0.050 |
Why?
|
| Adolescent | 1 | 2009 | 2100 | 0.050 |
Why?
|
| Glycosylation | 1 | 2022 | 18 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2022 | 15 | 0.050 |
Why?
|
| Proline | 1 | 2002 | 10 | 0.050 |
Why?
|
| Microsatellite Instability | 1 | 2022 | 10 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 18 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2018 | 577 | 0.050 |
Why?
|
| Fluorescence | 1 | 2021 | 8 | 0.050 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2021 | 11 | 0.050 |
Why?
|
| Loss of Heterozygosity | 1 | 2021 | 6 | 0.050 |
Why?
|
| Genomics | 1 | 2021 | 54 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 851 | 0.040 |
Why?
|
| Biological Availability | 1 | 2020 | 16 | 0.040 |
Why?
|
| Vasoconstriction | 1 | 2020 | 15 | 0.040 |
Why?
|
| Base Sequence | 2 | 2014 | 105 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 2015 | 129 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2024 | 1150 | 0.040 |
Why?
|
| RNA, Messenger | 2 | 2015 | 306 | 0.040 |
Why?
|
| beta-Arrestins | 1 | 2019 | 1 | 0.040 |
Why?
|
| Neoplasms, Experimental | 1 | 2019 | 10 | 0.040 |
Why?
|
| Models, Biological | 1 | 2021 | 318 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 37 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 198 | 0.040 |
Why?
|
| Endoplasmic Reticulum | 1 | 2018 | 26 | 0.040 |
Why?
|
| Action Potentials | 1 | 2018 | 82 | 0.040 |
Why?
|
| Sex Factors | 1 | 2019 | 454 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2017 | 61 | 0.030 |
Why?
|
| Time-Lapse Imaging | 1 | 2016 | 5 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2016 | 13 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2017 | 57 | 0.030 |
Why?
|
| A549 Cells | 1 | 2016 | 11 | 0.030 |
Why?
|
| Ubiquitination | 1 | 2016 | 15 | 0.030 |
Why?
|
| Fibrosis | 1 | 2016 | 31 | 0.030 |
Why?
|
| Neutrophils | 1 | 2017 | 95 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 102 | 0.030 |
Why?
|
| Atrophy | 1 | 2016 | 83 | 0.030 |
Why?
|
| Graft Survival | 1 | 2016 | 96 | 0.030 |
Why?
|
| Biopsy | 1 | 2016 | 196 | 0.030 |
Why?
|
| Twist-Related Protein 1 | 1 | 2015 | 3 | 0.030 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2015 | 7 | 0.030 |
Why?
|
| Arginine | 1 | 2015 | 17 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2015 | 37 | 0.030 |
Why?
|
| Cadherins | 1 | 2015 | 30 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 121 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 79 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 145 | 0.030 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2014 | 6 | 0.030 |
Why?
|
| Cognitive Dysfunction | 1 | 2024 | 990 | 0.030 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2014 | 9 | 0.030 |
Why?
|
| Cyclooxygenase 2 | 1 | 2014 | 29 | 0.030 |
Why?
|
| Hypertrophy | 1 | 2014 | 23 | 0.030 |
Why?
|
| Binding Sites | 1 | 2014 | 71 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2014 | 37 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 86 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2014 | 83 | 0.030 |
Why?
|
| Insulin Resistance | 1 | 2014 | 50 | 0.030 |
Why?
|
| Wound Healing | 1 | 2015 | 157 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2014 | 162 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2013 | 3 | 0.030 |
Why?
|
| Protein Kinase C beta | 1 | 2013 | 8 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2015 | 157 | 0.030 |
Why?
|
| Protein Structure, Secondary | 2 | 2004 | 21 | 0.030 |
Why?
|
| Cell Adhesion | 2 | 2004 | 31 | 0.030 |
Why?
|
| Ligands | 2 | 2004 | 38 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 2013 | 48 | 0.030 |
Why?
|
| Cell Survival | 1 | 2013 | 116 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2013 | 118 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2013 | 143 | 0.030 |
Why?
|
| Reference Standards | 1 | 2013 | 22 | 0.030 |
Why?
|
| Oligosaccharides | 1 | 2013 | 10 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2013 | 89 | 0.030 |
Why?
|
| Support Vector Machine | 1 | 2011 | 6 | 0.020 |
Why?
|
| Least-Squares Analysis | 1 | 2011 | 8 | 0.020 |
Why?
|
| Presenilin-1 | 1 | 2010 | 8 | 0.020 |
Why?
|
| Smad Proteins | 1 | 2010 | 3 | 0.020 |
Why?
|
| Metabolism | 1 | 2010 | 6 | 0.020 |
Why?
|
| Gels | 1 | 2010 | 11 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2010 | 22 | 0.020 |
Why?
|
| Nitriles | 1 | 2010 | 13 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2010 | 39 | 0.020 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2010 | 16 | 0.020 |
Why?
|
| Triazoles | 1 | 2010 | 29 | 0.020 |
Why?
|
| Bone Matrix | 1 | 2010 | 19 | 0.020 |
Why?
|
| Models, Animal | 1 | 2010 | 110 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2010 | 104 | 0.020 |
Why?
|
| Antipsychotic Agents | 1 | 2010 | 53 | 0.020 |
Why?
|
| Proteoglycans | 1 | 2010 | 131 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2010 | 96 | 0.020 |
Why?
|
| tau Proteins | 1 | 2010 | 225 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2010 | 512 | 0.020 |
Why?
|
| Aging | 1 | 2018 | 1483 | 0.020 |
Why?
|
| Caseins | 1 | 2008 | 1 | 0.020 |
Why?
|
| Manganese | 1 | 2008 | 1 | 0.020 |
Why?
|
| Phosphopeptides | 1 | 2008 | 1 | 0.020 |
Why?
|
| Ovalbumin | 1 | 2008 | 6 | 0.020 |
Why?
|
| Aluminum | 1 | 2008 | 9 | 0.020 |
Why?
|
| Iron | 1 | 2008 | 14 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2008 | 23 | 0.020 |
Why?
|
| Titanium | 1 | 2008 | 168 | 0.020 |
Why?
|
| DNA Primers | 1 | 2004 | 51 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2004 | 50 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 2002 | 3 | 0.010 |
Why?
|
| Drug Stability | 1 | 2002 | 3 | 0.010 |
Why?
|
| Basement Membrane | 1 | 2002 | 10 | 0.010 |
Why?
|
| Biophysical Phenomena | 1 | 2002 | 26 | 0.010 |
Why?
|
| Biophysics | 1 | 2002 | 32 | 0.010 |
Why?
|